Page last updated: 2024-12-11
hemiasterlin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
hemiasterlin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 5352092 |
CHEMBL ID | 185151 |
SCHEMBL ID | 57313 |
MeSH ID | M0440841 |
Synonyms (17)
Synonym |
---|
nsc-695242 |
NSC695242 , |
hemiasterlin |
CHEMBL185151 |
(e,4s)-4-[[(2s)-3,3-dimethyl-2-[[(2s)-3-methyl-2-(methylamino)-3-(1-methylindol-3-yl)butanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid |
milnamide b |
l-valinamide, n,beta,beta,1-tetramethyl-l-tryptophyl-n-((1s,2e)-3-carboxy-1-(1-methylethyl)-2-buten-1-yl)-n,3-dimethyl- |
6s0t7u2i3f , |
157207-90-4 |
(-)-hemiasterlin |
unii-6s0t7u2i3f |
SCHEMBL57313 |
l-valinamide, n,.beta.,.beta.,1-tetramethyl-l-tryptophyl-n-((1s,2e)-3-carboxy-1-(1-methylethyl)-2-buten-1-yl)-n,3-dimethyl- |
Q27265411 |
(s,e)-2,5-dimethyl-4-((s)-n,3,3-trimethyl-2-((s)-3-methyl-3-(1-methyl-1h-indol-3-yl)-2-(methylamino)butanamido)butanamido)hex-2-enoic acid |
HY-117371 |
AKOS040752003 |
Research Excerpts
Overview
Hemiasterlin is a natural product derived from marine sponges. It binds to the Vinca-peptide site in tubulin, disrupts normal microtubule dynamics, and, at stoichiometric amounts, depolymerizes microtubules.
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (7)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID354406 | Cytotoxicity activity against human MCF7 cells expressing p53 mutant by MTT assay | 2003 | Journal of natural products, Feb, Volume: 66, Issue:2 | Synthesis and antimitotic/cytotoxic activity of hemiasterlin analogues. |
AID248904 | Concentration required to kill human epidermoid KB-3-1 cell lines containing very low levels of P-glycoprotein after 3 days of continuous exposure | 2004 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21 | Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment. |
AID248874 | Concentration required to kill human epidermoid KB85 cell lines containing moderate levels of P-glycoprotein after 3 days of continuous exposure | 2004 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21 | Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment. |
AID248889 | Concentration required to kill human epidermoid KBV1 cell lines containing very high levels of P-glycoprotein after 3 days of continuous exposure | 2004 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21 | Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment. |
AID252057 | Percent inhibition of bovine microtubule-assisted protein (MAP) rich tubulin polymerisation at concentration of 0.3 uM; Not applicable | 2004 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21 | Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment. |
AID1304574 | Antiproliferative activity against human MCF7 cells after 20 hrs by microculture tetrazolium assay | 2016 | Journal of natural products, Mar-25, Volume: 79, Issue:3 | The Halicylindramides, Farnesoid X Receptor Antagonizing Depsipeptides from a Petrosia sp. Marine Sponge Collected in Korea. |
AID354405 | Antimitotic activity against human MCF7 cells expressing p53 mutant by MTT assay | 2003 | Journal of natural products, Feb, Volume: 66, Issue:2 | Synthesis and antimitotic/cytotoxic activity of hemiasterlin analogues. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (30)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 16 (53.33) | 29.6817 |
2010's | 13 (43.33) | 24.3611 |
2020's | 1 (3.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 29.28
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.28) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (6.67%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 28 (93.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |